Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2012

Hematopoietic Stem Cell Transplantation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2012', provides an overview of the Hematopoietic Stem Cell Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation.
- A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation pipeline depth and focus of Hematopoietic Stem Cell Transplantation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hematopoietic Stem Cell Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hematopoietic Stem Cell Transplantation 7
Hematopoietic Stem Cell Transplantation Therapeutics under Development by Companies 9
Hematopoietic Stem Cell Transplantation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Hematopoietic Stem Cell Transplantation Therapeutics – Products under Development by Companies 14
Hematopoietic Stem Cell Transplantation Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Hematopoietic Stem Cell Transplantation Therapeutics Development 16
Athersys, Inc. 16
GlaxoSmithKline plc 17
Celldex Therapeutics, Inc. 18
Pharmalink AB 19
Polyphor Ltd. 20
Bellicum Pharmaceuticals, Inc. 21
Hematopoietic Stem Cell Transplantation – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Ronacaleret - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MultiStem - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Busulipo - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
POL6326 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CDX-301 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TXA127 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Flu-ATG - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CaspaCIDe DLI - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Hematopoietic Stem Cell Transplantation Therapeutics – Drug Profile Updates 38
Hematopoietic Stem Cell Transplantation Therapeutics - Dormant Products 44
Hematopoietic Stem Cell Transplantation – Product Development Milestones 45
Featured News & Press Releases 45
Jul 09, 2012: Chimerix Announces BK Virus Data In Late-Breaking Poster Session At 24th International Congress Of Transplantation Society 45
Feb 01, 2012: Athersys Announces Phase I clinical trial Results Of MultiStem For Hematopoietic Stem Cell Transplant Support And Prevention Of Graft-Versus-Host Disease 45
Jan 17, 2012: Celldex Therapeutics Initiates Phase I Clinical Trial Of CDX-301 For Hematopoietic Stem Cell Transplantation 48
Nov 11, 2011: Chimerix Announces Late-Breaking Poster Presentation At Kidney Week 2011 Annual Meeting 49
Oct 17, 2011: Athersys Confirms Completion Of Patient Enrollment For Phase I Study Of MultiStem For Hematopoietic Stem Cell Transplant Support 49
Jul 26, 2011: TikoMed Receives Orphan Drug Designation For TM-400 From FDA 50
Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference 51
Jul 13, 2011: Chimerix Commences Phase II Study Of CMX001 For Prevention Of AdV In Ped & Adult Hematopoietic Stem Cell Transplant Patients 51
Jul 06, 2011: Gentium Announces NDA Submission For Defibrotide 52
May 25, 2011: Athersys Announces Positive Interim Results From Ongoing Phase I Study Of MultiStem For Hematopoietic Stem Cell Transplant Support And Graft-Versus-Host Disease 53
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products Under Development for Hematopoietic Stem Cell Transplantation, H2 2012 7
Products under Development for Hematopoietic Stem Cell Transplantation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Athersys, Inc., H2 2012 16
GlaxoSmithKline plc, H2 2012 17
Celldex Therapeutics, Inc., H2 2012 18
Pharmalink AB, H2 2012 19
Polyphor Ltd., H2 2012 20
Bellicum Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Hematopoietic Stem Cell Transplantation Therapeutics – Drug Profile Updates 38
Hematopoietic Stem Cell Transplantation Therapeutics – Dormant Products 44

List of Figures
Number of Products under Development for Hematopoietic Stem Cell Transplantation, H2 2012 7
Products under Development for Hematopoietic Stem Cell Transplantation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26